Danish biotech company sold to Swedes

The Swedish company Ascelia, managed by a former Sunstone director, has acquired the biotech company Oncoral and its cancer candidate, which is currently being tested in phase I trials at Herlev Hospital in Denmark.

Sverige Danmark svensk dansk
Photo: Colourbox

Malmö-based Ascelia Pharma – previously CMC Contrast – has been shopping on the Danish side of Öresund and acquired the phase I company Oncoral.

”We have been looking very, very intensively for a drug with a low risk profile in the development phase and a desirable patient group that would give us the opportunity of developing significantly better drugs. Oncoral had it all,” says Ascelia’s Danish CEO, Magnus Corfitzen, in an interview with MedWatch.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles